Researchers Create New MR Contrast Agent That Can Locate And Differentiate Between Aggressive And Slow-Growing Breast Cancer.

Wednesday, September 27, 2017

DOT Med News (9/26, Fischer) reports that scientists “have created a new MR contrast agent that can locate and differentiate between aggressive and slow-growing, low-risk types of breast cancer at early stages.” According to DOT Med News, “The gadolinium-based agent lights up cancer biomarkers during scans, overcoming the low sensitivity of MR for imaging markers, and produces signals with different shades ofbrightness that contrast aggressive from slow-growing, low-risk types of cancer.” The research was published in Nature Communications.

Breast MR Imaging May Improve Depiction Of DCIS Components Of Invasive Breast Cancers Prior To Surgery, Research Suggests.

Thursday, September 21, 2017
Diagnostic Imaging (9/20) reports that research suggests “breast MR imaging improves depiction of ductal carcinoma in situ (DCIS) components of invasive breast cancers before surgery.” The findings were published in Radiology.

Women Still Value Mammography’s Benefits Over Potential “Harms,” Study Suggests.

Monday, September 18, 2017
Aunt Minnie (9/18, Yee) reports researchers surveyed 429 women and found that fewer than 20 percent of respondents “knew about breast cancer overdiagnosis and overtreatment,” and those who did said they do not find information about overdiagnosis and treatment “believable or persuasive.” Rebekah Nagler, PhD, of the Hubbard School of Journalism and Mass Communication at University of Minnesota, said, “Despite increasing dissemination of information about cancer overdiagnosis and overtreatment via both news media coverage and health-related websites, patient awareness remains low.” The findings were published in Medical Care. 

Mobile Mammography Programs Only “Somewhat Successful,” Study Says.

Thursday, September 14, 2017

Aunt Minnie (9/14, Yee) reports that a new study shows that mobile mammography programs are “a move in the right direction, but more work needs to be done to better assist women who make use of mobile mammography,” including to ensure follow-up. At team led by Dr. Madelene Lewis of the Medical University of South Carolina in Charleston found that its mobile program was “only somewhat successful” in addressing the issues of getting underserved women screened. The study looked at “1,433 screening mammography exams performed in a mobile unit in 2014, and 1,434 exams performed at the university’s cancer center during the same year.” Lewis’ team “recorded associations between the two locations and characteristics such as health insurance, race, marital status, geographic area, adherence to screening guidelines, and recall rates.” 

FDA Grants Clearance To Mammogram Device That Allows Patients To Control Pressure.

Friday, September 1, 2017

MedPage Today (9/1, Frieden) reported that the Food and Drug Administration “approved a device to allow patients to control the pressure on their breast while undergoing a mammogram.” According to Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics and Radiological Health at the FDA’s Center for Devices and Radiological Health, “Regular mammograms are an important tool in detecting breast cancer. However, some patients may experience anxiety or stress about the discomfort from the compression during the mammogram. This device allows patients some control over the amount of compression for their exam.” The Senographe Pristina with Self-Compression device is by GE Healthcare and “employs a handheld wireless remote control that patients use to adjust the compression force after the breast has been positioned.” Additional coverage is provided by Aunt Minnie (9/1).